Intellia Therapeutics, Inc. - Common Stock (NTLA)

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) --

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Edison International (NYSEEIX), Elastic N.V. NYSE:ESTCNYSEESTC)(NASDAQ:NTLANASDAQNTLA, and Merck & Co., Inc. (NYSE: MRKNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQNTLA) and certain of its officers.

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, Inc. (NASDAQNTLA) securities between June 30, 2024 and January 28, 2025. Intellia describes itself as a leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQNTLA) and certain of its officers.

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQNTLA) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”). Investors have until April 14, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, Inc. (NASDAQNTLA) securities between June 30, 2024 and January 28, 2025. Intellia describes itself as a leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQNTLA) between July 30, 2024 and January 8, 2025. Intellia describes itself as a “leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.”

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQNTLA) between July 30, 2024 and January 8, 2025, inclusive.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQNTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options

CRISPR Therapeutics AG (NASDAQCRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTXNASDAQVRTX)

Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF). CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestive systems and other organs. CF can result in life-threatening infections, respiratory failure and other serious complications.

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Voyager Therapeutics Inc. (NASDAQVYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQVRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.

According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.